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Given that elevated serum levels of hepatitis B virus (HBV) DNA 
are associated with an increased risk for liver cirrhosis or hepato-
cellular carcinoma (HCC),1 the mainstay of hepatitis B treatment is 
antiviral therapy (AVT) to suppress viral replication. Currently, 
commencement of AVT depends on not only serum HBV-DNA lev-
el but also serum alanine aminotransferase (ALT) level, hepatitis B 
e antigen status, and the presence of liver cirrhosis or HCC.2,3 
However, even in cases with normal transaminase levels, patients 
with high HBV-DNA and histologically proven necro-inflammation 
or fibrosis (≥F2 grade) may be candidates for AVT, with the goal 
of minimizing disease progression.
As reported in the most recent issue of Clinical Molecular and 
Hepatology, Cristina et al.4 found that approximately 14% of sub-
jects with chronic HBV infection and normal transaminase levels 
had significant liver fibrosis (≥7.9 kPa), as assessed by transient 
elastography (TE). However, there was concern as to whether pa-
tients with well-controlled inflammation may still experience dis-
ease progression. In this article, we address several of the above-
mentioned concerns.
First, in considering that the enrolled subjects tended to be 
more obese (mean body mass index 27±5 kg/m2) compared to 
previous studies,5,6 they were more likely to have concomitant liver 
disease other than chronic HBV infection.7,8 Obesity is strongly as-
sociated with fatty liver disease and metabolic syndrome, both of 
which can accelerate hepatic fibrosis.8,9 Steatohepatitis proven on 
histology may exist even in cases of normal baseline transaminase 
levels, which suggests that elevated ALT is not predictive of 
necro-inflammation or fibrosis. The suggestion that patients with 
altered transaminases are more likely to have a higher fibrotic 
burden implies that this cohort should include patients with ste-
atohepatitis with, at a minimum, indolent histological activity. 
Furthermore, increased organ fat can lead to an overestimation of 
liver stiffness in some patients.10 Taken together, these findings 
suggest that combined fatty liver disease with hepatic necro-in-
flammation, even in the presence of “normal” transaminase lev-
els, may result in a higher proportion of patients with fibrosis in 
this cohort.
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Second, Cristina et al.4 defined significant fibrosis as stage ≥ F2 
(≥7.9 kPa) using TE. Although the presence of significant fibrosis 
is considered a hallmark of progressive disease, the diagnostic 
performance of TE in classifying patients as F2 or higher is rela-
tively limited. Receiver operating characteristic for ≥ F2 was highly 
variable in a recent meta-analysis, ranging between 68% and 
100%.11 Therefore, TE alone is insufficient in clinical practice, es-
pecially in the diagnosis of grades F0–2. Furthermore, it has been 
suggested that validated biomarker testing (i.e., FibroTest) is su-
perior in differentiating F0 vs. F1 vs. F2.12
Lastly, Cristina et al.4 allocated study participants only when 
normal transaminase levels were maintained over 3 consecutive 
tests for 9 months. However, viral phases are subject to change 
depending on the various interactions between host immunity 
and viral replication. As such, viral phases are not necessarily se-
quential,13 and the duration of 9 months used to define normal 
transaminase levels might in fact be insufficient. Kim et al.14 re-
cently demonstrated that untreated immune tolerant (IT) phase 
patients with normal transaminase levels are also subject to a sig-
nificant risk for disease progression. This study may be subject to 
similar criticism, because IT-phase patients were defined through 
only 1 year of observation. Taken together, these results indicate 
that patients classified as having well-controlled inflammation at 
baseline may eventually shift to an immune-active status over an 
extended clinical course. As such, viral and biochemical status 
should be continuously tracked during the follow-up.
Although AVT is recommended in patients with significant fi-
brosis as proven by liver biopsy even in those with normal ALT 
level,2,3 it is not always feasible to perform biopsies depending on 
the presence of fibrosis. Therefore, noninvasive surrogates for liver 
fibrosis such as TE, shear wave elastography, or magnetic reso-
nance imaging, all of which are more accurate than ultrasound in 
assessing the overall fibrotic burden, may be required to identify 
the optimal candidates for AVT among chronic hepatitis B pa-
tients with normal transaminase levels.7,15 As Cristina et al.4 de-
scribed, the use of noninvasive imaging surrogates may be neces-
sary to identify chronic HBV patient subgroups where AVT could 
potentially reduce the risk of disease progression. 
In conclusion, the study by Cristina et al.4 confirm that a thor-
ough assessment of liver fibrosis is required to stratify subgroups 
of patients with normal transaminase levels, to select optimal 
candidates for AVT, when histological information is not available.
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